Therefore, because our findings indicate PI3K p110γ inhibition alone enhances CD8+ T-cell recruitment and preserves CD8+ T-cell function, this provides a rationale to combine PI3K p110γ inhibition with PD-L1 checkpoint inhibitors against poorly immunogenic HNSCC. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.